Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Neoplasms 45Neoplasm Metastasis 3Neoplasm, Residual 2Adenocarcinoma 2Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Paclitaxel 9Carboplatin 9pembrolizumab 7Radiotherapy 7Cisplatin 5Axitinib 4Pemetrexed 3Nivolumab 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2fludarabine 2dacomitinib 2catumaxomab 2Trastuzumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Nurses 2Interleukin-2 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vatalanib 1temsirolimus 1sovateltide 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Blood Specimen Collection × Tumor-Agnostic × Clear all
NCT00349830 2026-02-10

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Stanford University

Recruiting
2,000 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡